Open AccessRole of epithelial-mesenchymal transition in chemoresistance in pancreatic ductal adenocarcinoma
Author(s) -
Xinying Hu,
Wei Chen
Publication year - 2021
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v9.i19.4998
Subject(s) - medicine , epithelial–mesenchymal transition , pancreatic cancer , pancreatic ductal adenocarcinoma , drug resistance , cancer research , adenocarcinoma , chemotherapy , oncology , cancer , bioinformatics , metastasis , biology , microbiology and biotechnology
Pancreatic cancer (PC) is the seventh leading cause of cancer death worldwide. The vast majority of patients who have PC develop metastases, resulting in poor treatment effects. Although great progress in therapeutic approaches has been achieved in recent decades, extensive drug resistance still persists, representing a major hurdle to effective anticancer therapy for pancreatic ductal adenocarcinoma (PDAC). Therefore, there is an urgent need to better understand the drug resistance mechanisms and develop novel treatment strategies to improve patient outcomes. Numerous studies suggest that chemoresistance is closely related to epithelial-mesenchymal transition (EMT) of PDAC cells. Thus, this article summarizes the impact of EMT on PDAC from the perspective of chemotherapy resistance and discusses the possible novel applications of EMT inhibition to develop more effective drugs against PDAC.